Suggested remit - To appraise the clinical and cost effectiveness of depatuxizumab mafodotin within its marketing authorisation for treating newly diagnosed EGFR-amplified glioblastoma multiforme
Following on from information provided to NICE by the company in June 2019, the appraisal of Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1466

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
04 June 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal which closed on 22 May 2019. The company that manufacturer depatuxizumab mafodotin have advised NICE that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information NICE will not be progressing with the scoping exercise at this time. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course if required. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)
21 March 2017 Referral
21 March 2017 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual